CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia

Summary

CD70 is a promising target for immunotherapy because it is overexpressed in T-cell lymphoma (TCL) and acute myeloid leukemia (AML) tumor cells but is found in deficient levels in normal tissues and hematopoietic stem cells. This study aims to evaluate the safety and efficacy of CD70-targeted CAR-NK (CD70-CAR-NK) cells in patients with relapsed and refractory TCL and AML.

Timeline

Start

2024-12-01

Primary completion

2027-11-30

Completion

2028-11-30

Drugs

Indications